Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 09, 2023

SELL
$0.12 - $0.21 $64,800 - $113,401
-540,007 Reduced 33.41%
1,076,196 $161,000
Q3 2022

Nov 02, 2022

BUY
$0.24 - $1.11 $385,324 - $1.78 Million
1,605,519 Added 15027.32%
1,616,203 $435,000
Q2 2022

Aug 01, 2022

BUY
$0.41 - $0.91 $69 - $153
169 Added 1.61%
10,684 $4,000
Q1 2022

May 04, 2022

SELL
$0.79 - $1.59 $237 - $477
-300 Reduced 2.77%
10,515 $5,000
Q4 2021

Feb 07, 2022

SELL
$1.36 - $2.94 $455 - $984
-335 Reduced 3.0%
10,815 $15,000
Q3 2021

Nov 02, 2021

BUY
$2.97 - $4.84 $33,115 - $53,966
11,150 New
11,150 $34,000
Q2 2021

Aug 03, 2021

SELL
$3.71 - $5.13 $138,286 - $191,215
-37,274 Closed
0 $0
Q1 2021

May 04, 2021

SELL
$4.08 - $14.75 $440,754 - $1.59 Million
-108,028 Reduced 74.35%
37,274 $160,000
Q4 2020

Feb 01, 2021

SELL
$11.06 - $14.01 $186,261 - $235,942
-16,841 Reduced 10.39%
145,302 $1.61 Million
Q3 2020

Nov 09, 2020

BUY
$10.26 - $14.55 $379,650 - $538,393
37,003 Added 29.57%
162,143 $1.96 Million
Q2 2020

Aug 07, 2020

SELL
$7.11 - $13.76 $58,472 - $113,162
-8,224 Reduced 6.17%
125,140 $1.72 Million
Q1 2020

May 04, 2020

SELL
$5.71 - $15.85 $70,038 - $194,416
-12,266 Reduced 8.42%
133,364 $1.03 Million
Q4 2019

Feb 06, 2020

BUY
$9.6 - $17.75 $87,734 - $162,217
9,139 Added 6.7%
145,630 $2.22 Million
Q4 2019

Feb 04, 2020

BUY
$9.6 - $17.75 $805,152 - $1.49 Million
83,870 Added 159.39%
136,491 $1.83 Million
Q3 2019

Nov 12, 2019

BUY
$12.16 - $21.0 $619,661 - $1.07 Million
50,959 Added 3066.13%
52,621 $640,000
Q4 2018

Feb 05, 2019

SELL
$10.24 - $15.49 $3,246 - $4,910
-317 Reduced 16.02%
1,662 $21,000
Q3 2018

Nov 01, 2018

BUY
$15.53 - $19.97 $30,733 - $39,520
1,979 New
1,979 $31,000

Others Institutions Holding ATNX

About Athenex, Inc.


  • Ticker ATNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 156,790,000
  • Market Cap $1.57M
  • Description
  • Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...
More about ATNX
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.